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ABSTRACT 1 
Phyllomedusine frogs are an extraordinary source of biologically active peptides. At least 8 2 
families of antimicrobial peptides have been reported in this frog clade, the dermaseptins 3 
being the most diverse. By a peptidomic approach, integrating molecular cloning, Edman 4 
degradation sequencing and tandem mass spectrometry, a new family of antimicrobial 5 
peptides have been identified in Cruziohyla calcarifer. These 15 novel antimicrobial peptides 6 
of 20–32 residues in length are named cruzioseptins. They are characterized by having a 7 
unique shared N-terminal sequence GFLD– and the sequence motifs –VALGAVSK– or –8 
GKAAL(N/G/S) (V/A)V– in the middle of the peptide. Cruzioseptins have a broad spectrum 9 
of antimicrobial activity and low haemolytic effect. The most potent cruzioseptin was CZS-1 10 
that had a MIC of 3.77 µM against the Gram positive bacterium, Staphylococcus aureus and 11 
the yeast Candida albicans. In contrast, CZS-1 was 3 –fold less potent against the Gram 12 
negative bacterium, Escherichia coli (MIC 15.11 µM). CZS-1 reached 100% haemolysis at 13 
120.87µM. Skin secretions from unexplored species such as C. calcarifer continue to 14 
demonstrate the enormous molecular diversity hidden in the amphibian skin. Some of these 15 
novel peptides may provide lead structures for the development of a new class of antibiotics 16 
and antifungals of therapeutic use. 17 
SIGNIFICANCE 18 
Through the combination of molecular cloning, Edman degradation sequencing, tandem mass 19 
spectrometry and MALDI-TOF MS we have identified a new family of 15 antimicrobial 20 
peptides in the skin secretion of Cruziohyla calcarifer. The novel family is named 21 
“Cruzioseptins” and contain cationic amphipathic peptides of 20–32 residues. They have a 22 
broad range of antimicrobial activity that also includes effective antifungals with low 23 
haemolytic activity. Therefore, C. calcarifer has proven to be a rich source of novel peptides, 24 
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which could become leading structures for the development of novel antibiotics and 1 
antifungals of clinical application. 2 
INTRODUCTION 3 
Antimicrobial peptides (AMPs) are a diverse group of oligopeptides that constitute the 4 
effector molecules of the innate immune response. They occur in all domains in nature, 5 
including bacteria, protozoa, fungi, molluscs, arthropods, vertebrates, and plants. AMPs have 6 
a broad spectrum of antimicrobial activity and provide protection against bacteria, fungi, 7 
parasites and viruses; however, recent research has provided evidence of additional roles in 8 
inflammation, immunity and wound healing [1].  9 
AMPs are extremely diverse in primary structure. There is no clear correlation between 10 
structure, potency and selectivity. However, size, charge, hydrophobicity, and amphipathicity 11 
are crucial physicochemical properties for their biological activity [1,2]. Most antimicrobial 12 
peptides contain between 8–45 amino acids and a positive net charge of +2–+6 at pH7 [3]. In 13 
addition, AMPs are usually amphipathic, with a hydrophobic face containing approximately 14 
50% of hydrophobic amino acids. The main mechanism of action involves electrostatic 15 
contact of cationic peptides with the anionic membrane of the target microorganisms 16 
followed by insertion into the membrane interior. The hydrophobic face interacts with the 17 
lipid core while the hydrophilic face interacts with the phospholipids of the cell membrane, 18 
and various models have been described, including: carpet-like, toroidal pore, and barrel-19 
stave [1,2]. In addition, some natural AMPs undergo post translational modifications (PTMs) 20 
that are required for their antimicrobial function. Common PTMs include: phosphorylation, 21 
replacement of L-amino acids with their D-isomers, methylation, amidation, glycosylation, 22 
and disulphide bridges [4].  23 
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Amphibian skin is one of the richest sources of antimicrobial peptides. Until 2015, around 1 
1600 AMPs had been reported from 165 species and 26 genera [5]. These peptides have been 2 
arranged into at least 100 peptide families based on sequence similarities. Remarkably, more 3 
than 165 antimicrobial peptides have been reported in the dermaseptin superfamily which 4 
occurs in the skins of Central and South American frogs that belong to the Phyllomedusinae 5 
subfamily including the genera: Phyllomedusa (12 spp.), Agalychnis (5 spp.), and 6 
Phasmahyla (1 sp.) [5–8].  7 
An important characteristic of the members of the dermaseptin superfamily are the highly 8 
conserved amino acid sequences in their precursor N-terminal regions that correspond to the 9 
signal peptide and acidic spacer peptide. This conservation usually extends to the non-10 
translated regions at the 5’ side of the precursor nucleotide sequence. Indeed, the extremely 11 
conserved sequences have allowed the design of primers able to target this region and have 12 
been instrumental in the discovery of a large number of related peptides. These peptides have 13 
been classified in the following families: dermaseptins sensu stricto, dermatoxins, phylloxins, 14 
phylloseptins, plasticins, medusins, caerin-related peptides and orphan peptides [8–18].  15 
Most studies have been focused on Phyllomedusa and Agalychnis, while other genera such as 16 
Cruziohyla remain unexplored. Cruziohyla includes two species: C. calcarifer that occurs in 17 
the Caribbean lowlands from eastern Honduras to the Pacific lowlands of northwestern 18 
Ecuador, and C. craspedopus that occurs in the Amazon lowlands from Colombia to Peru 19 
[19]. Cruziohyla calcarifer was recently relocated from the genus Agalychnis to the new 20 
genus Cruziohyla [20] and, considering their taxonomic proximity to Agalychnis, it was 21 
presumed that this taxon also produce bioactive peptides in their skin. 22 
Several studies have demonstrated the robustness of complementing data from shotgun 23 
molecular cloning, Edman N-terminal sequencing and tandem mass sequencing for 24 
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peptidomic studies on frog skin secretions [10,21–23]. In the current study, a new family of 1 
15 antimicrobial peptides is reported in the splendid leaf frog, Cruziohyla calcarifer and are 2 
named cruzioseptins. These contain an N-terminal sequence motif, GFLD– and the sequences 3 
–VALGAVSK– or –GKAAL(N/G/S) (V/A)V– in the mid-regions of their mature peptides. 4 
Cruzioseptins showed a broad spectrum of antimicrobial activity against Staphylococcus 5 
aureus, Escherichia coli, and Candida albicans with low haemolytic effects. 6 
METHODS 7 
Skin secretion extraction 8 
Two adult specimens were collected in northwestern Ecuador (Esmeraldas Province, 9 
Durango) in November 2013. Four captive reared sub-adult specimens (from Esmeraldas 10 
Province, Reserve Otokiki) were provided in 2015 by Centro Jambatu for Research and 11 
Conservation of Amphibians in Ecuador. Skin secretions were obtained after gently 12 
massaging the dorsal side of the animals. Secretions were washed off the animals with 13 
distilled water. Samples were immediately frozen and stored at -20ºC. The frogs collected in 14 
the field were returned to their habitat after the extraction. Samples were freeze-dried for 15 
analysis in Queen’s University Belfast.  16 
Twelve additional samples were taken from a group of 13-month-old captive bred frogs, 17 
whose parental line came from a Costa Rican population.  Specimens were housed in terraria 18 
as pets in Belgium and Austria. Samples were extracted in the same way as described above, 19 
but instead of freeze-dried they were acidified with TFA and were transported at room 20 
temperature to the laboratory facilities in Queen’s University Belfast.  21 
Molecular cloning 22 
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Lyophilized skin secretions were dissolved in buffer A (99.95% water; 0.05% trifluoroacetic 1 
acid), pooled, and aliquoted into two tubes. One was employed for molecular cloning and the 2 
other for HPLC fractionation. 3 
One aliquot, equivalent to skin secretion of 2.5 frogs of the Ecuadorian sample, or 1.3 mg of 4 
the Costa Rican sample, was dissolved in 1ml of cell lysis/ binding buffer, and 5 
polyadenylated mRNA was isolated using magnetic Dynabeads Oligo (dTs) as described by 6 
the manufacturer (Dynal Biotec, UK). Isolated mRNA was subjected to 3’-rapid 7 
amplification of cDNA by using the SMART-RACE kit (Clontech, UK). In brief, three sets 8 
of 3’-RACE reactions were employed. Firstly, 3’RACE used a nested universal primer (NUP) 9 
provided with the kit and the sense primer 1 (S1: 5’-10 
CAGCACTTTCTGAATTACAAGACCAA-3’) that was complementary to the signal 11 
sequence of the phylloseptin-S5 precursor of Phyllomedusa sauvagii. Secondly, 3’RACE 12 
employed an NUP primer and the sense primer 2 (S2: 5’ 13 
TAGACCAAACATGGCTTTCCTGA) designed to target the signal sequence of the first 14 
antimicrobial peptide of Cruziohyla calcarifer (CZS-1), which was first identified with the 15 
primer sense 1 described above. The third 3’RACE included an NUP primer and the sense 16 
primer 3 (S3: 5’-AAGAGAGGCTTCCTGGAT-3’), which was also designed based on the 17 
sequence of CZS-1 but this time targeting the sequence corresponding to the first 4 amino 18 
acids of the mature sequence of the CZS-1 peptide. These primers were designed employing 19 
Primer3 and Primer-BLAST online softwares. The 3’-RACE reactions were purified and 20 
cloned using a pGEM-T vector system (Promega Corporation) and sequenced using an ABI 21 
3100 automated sequence.  22 
 Reverse-phase HPLC fractionation and Edman degradation 23 
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The second aliquot of freeze-dried skin secretion (corresponding to 2.5 frogs) was dissolved 1 
in 1.2 ml of buffer A (99.95% H2O, 0.05% trifluoroacetic acid) and clarified by 2 
centrifugation. 1 ml supernatant was subjected to reverse phase HPLC employing Waters 3 
Binary pump HPLC system fitted with an analytical column Phenomenex Jupiter C18 (4.6 x 4 
250 mm). Peptides were eluted with a linear gradient formed from 100% buffer A (99.95% 5 
H2O, 0.05% trifluoroacetic acid) to 100% buffer B (80.00% Acetonitrile, 19.95% H2O, 6 
0.05% trifluoroacetic acid) in 240 min at a flow rate 1 ml/min. Fractions (1 ml) were 7 
collected every minute. Detection at 214 and 280 nm was continuous.  8 
Skin secretion of two specimens of C. calcarifer from a Costa Rican population was 9 
subjected to reverse-phase HPLC using a Diphenyl column C18. Peptides were eluted in a 10 
gradient from 1% buffer A (99.95:0.05% H2O/trifluoroacetic acid) to 80% buffer B 11 
(80.00:19.95:0.05% acetonitrile/H2O/trifluoroacetic acid) in 80 min and fractions were 12 
collected every minute. Those fractions were tested for antimicrobial activity and the active 13 
fractions 47-53, 59 were re-chromatographed on a Vydac C18 column until clear peaks were 14 
obtained. Those samples were sequenced by automated Edman degradation. These analyses 15 
were performed in Chris Shaw lab 15 years ago (unpublished data).  16 
MALDI-TOF MS 17 
The molecular masses of peptides and proteins in each chromatographic fraction were 18 
analysed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 19 
(MALDI-TOF MS) on a linear time-of-flight Voyager DE mass spectrometer (Perceptive 20 
Biosystems, MA, USA) in positive detection mode employing α-cyano-4-hydroxycinnamic 21 
acid matrix. Two microliters of sample plus 1 µl of matrix (10 mg/ml) were allowed to dry 22 
and were later analysed in the range of 500–5000 Da. 23 
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Tandem mass spectrometry sequencing  1 
20 µl of the remaining skin secretion fraction were diluted in buffer A and was pumped 2 
directly onto an analytical HPLC column (Phenomenex C-18; 4.6x150 mm) connected to an 3 
LCQ Fleet ESI ion-trap mass spectrometer (Thermo Fisher, San Jose, CA, USA). The linear 4 
elution gradient was formed from 100% buffer A (99.90% H2O, 0.1% formic acid) to 100% 5 
buffer B (19.9% H2O, 80% acetonitrile, 0.1% formic acid) in 135 min at a flow rate 20 6 
µl/min. Mass analysis was performed in a positive ion mode with acquired spectra in the 7 
range of m/z 500–2000 with >50% relative intensity during HPLC-MS. Parameters for 8 
electrospray ionization ion-trap mass spectrometry (ESI/MS) were: spray voltage +4.5kV, 9 
drying gas temperature 320ºC, drying gas flow 200 µl/min, and maximum accumulation time 10 
–for the ion trap– 350 ms. The first mass analysis was performed in full scan mode, then 11 
peptide ions with >50% relative intensity were selected for fragmentation by collision 12 
induced dissociation (CID), to generate b and y ions that were detected in a second mass 13 
analysis. The instrument was controlled by Xcalibur software (Thermo, USA) and data 14 
analysis was performed using Proteome Discover 1.0 (Thermo, USA). SequestTM algorithm 15 
was employed to compare the acquired fragment ion profiles with the theoretical fragment 16 
ions generated from a FASTA database specific for this species built by molecular cloning 17 
(as described above) to confirm the amino acid sequences of individual peptides.  18 
Solid phase peptide synthesis (SPPS) 19 
Three peptides CZS-1: GFLDIVKGVGKVALGAVSKLF-amide, CZS-2: 20 
GFLDVIKHVGKAALGVVTHLINQ-amide, and CZS-3: 21 
GFLDVVKHIGKAALGAVTHLINQ-amide were chemically synthetized by solid phase 22 
Fmoc chemistry using a Tribute peptide synthesizer (Protein technologies, Inc). After 23 
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cleavage from resin and de-protection, each peptide was purified by HPLC and their degrees 1 
of purity were analysed by MALDI-TOF mass spectrometry. 2 
Antimicrobial assays 3 
Antimicrobial screening 4 
500 µl of each HPLC fraction were dried in a vacuum concentrator and later diluted in 10 µl 5 
of phosphate buffered saline (PBS). Mueller agar plates with Escherichia coli, 6 
Staphylococcus aureus and Candida albicans in a 106 CFU/ml concentration were prepared 7 
and 12 holes were prepared with a sterile Pasteur pipette. 2 µl of each fraction were 8 
transferred to one hole of each plate to be tested against the 3 microorganisms. Plates were 9 
incubated at 37ºC overnight and inhibition zones were recorded as antimicrobial activity. 10 
Minimal inhibitory concentration MIC and minimal bactericidal concentration MBC assays 11 
MICs of the synthetic peptides were determined against E. coli, S. aureus and C. albicans. In 12 
brief, serial dilutions of each peptide in dimethylsulphoxide (DMSO) were prepared to obtain 13 
concentrations of 512, 256, 128, 64, 32, 16, 8, 4, 2, 1 x102 mg/L. Each microorganism in log 14 
phase was diluted to obtain the equivalent of 1x106 colony forming units (CFU)/ml for the 15 
bacteria and 1x105 CFU/ml for the yeast. Later, 2 µl of each peptide dilution were transferred 16 
to a 96 well sterile plate and 198 µl of the microorganism were added. As controls, 2 µl of 17 
DMSO was included instead of peptide and 200 µl of Mueller Hinton Broth in another well. 7 18 
replicates per peptide concentration were performed and the experiment was repeated 3 times 19 
in order to confirm the results. Plates were incubated at 37ºC for 18–22 h. Growth was 20 
monitored at 550 nm in an ELISA plate reader. Later, 10 µl of each concentration without 21 
visual growth was sub-cultured on Mueller Hinton agar plates. Plates were incubated at 37ºC 22 
overnight. MBCs were recorded as the minimal concentration without any growth 23 
occurrence.  24 
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Haemolysis assay 1 
A suspension of red blood cells (2%) was prepared with defibrinated horse blood (ICS 2 
Biosciences) and it was challenged with serial dilutions of the tested peptides resembling the 3 
same concentrations employed in the antimicrobial assays previously described. In brief, 200 4 
µl of blood cell suspension were incubated with 200 µl of each diluted peptide and they were 5 
incubated at 37ºC for 120 min. Later, samples were centrifuged and supernatants were 6 
transferred to a 96 well plate. Lysis of red blood cells was analysed in an ELISA plate reader 7 
at λ=550 nm. For negative controls, phosphate buffered saline was added to the cells instead 8 
of peptide, and for positive controls, phosphate buffered saline with 2% (v/v) Triton X-100 9 
(Sigma-Aldrich) was employed. The concentrations that produce 100% haemolysis are 10 
reported. 11 
Bioinformatic analysis 12 
Nucleotide sequences were analysed by MEGA6.0 and compared by employing the BLAST 13 
tool using databases in the National Centre for Biotechnology Information (NCBI) [24,25]. 14 
Signal peptides were predicted using the SignalP 4.1 server and theoretical peptide masses 15 
were calculated with the peptide mass calculator v3.2 [26,27]. Secondary structure prediction 16 
was performed using the GOR4 programme and the physicochemical properties of the 17 
peptides were calculated using HeliQuest Computational Parameters and Peptide property 18 
calculator Bachem [28-30].  19 
RESULTS 20 
Molecular cloning of novel antimicrobial peptide precursor-encoding cDNAs 21 
Seven full-length and four partial-length cDNAs encoding novel peptides were cloned from 22 
the cDNA library that was constructed from the skin secretion of Cruziohyla calcarifer 23 
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(Table 1 and Figure 1). The novel peptides are named Cruzioseptins (CZS) to represent their 1 
origin in Cruziohyla –a genus in honour of a Brazilian herpetologist, Carlos Alberto 2 
Gonçalves da Cruz, in recognition of his various contributions to knowledge of 3 
Phyllomedusinae [20]. The open reading frames of these sequences contained 195–231 4 
nucleotides. Translated amino acid sequences revealed that the precursors consisted of: (1) a 5 
putative signal peptide of 22 residues; (2) an acidic spacer peptide of 23 residues containing 2 6 
pro-peptide convertase processing sites; and (3) a mature peptide of 20–32 residues (Figure 7 
1). In addition, 6 of the 15 peptides were C-terminally amidated with a Gly (G) residue as the 8 
amide donor (Table 2). Nucleotide sequences were submitted to the GenBank (NCBI) under 9 
accession numbers: KX065078–KX065088. 10 
Each novel nucleotide sequence was analysed using the NCBI database and they showed 80–11 
91% similarity with dermaseptins from Phyllomedusa hypochondrialis (Accession number 12 
AM229015.1), Agalychnis annae (Accession number AJ005187.1), and P. bicolor 13 
(Accession number Y16564.1). In addition, the BLAST/p (protein/protein) comparisons 14 
using only the translated mature sequences of these peptides, showed a lower similarity (45–15 
90%) with dermaseptins. For example: CZS-4 was 45% similar to dermaseptin-B6 from P. 16 
bicolor (accession number AFR78287.1), CZS-6 was 65% similar to dermaseptin SVII from 17 
P. sauvagii (accession number CAD92230.1), and CZS-8 was 90% similar to 18 
dermadistinctin-L from P. distincta (accession number P83639.1). However, when the 19 
translated amino acid sequences of the mature peptides CZS-1 and 15 were subjected to 20 
BLAST/p analysis, no significant hits were found, not with any amphibian skin antimicrobial 21 
peptide or with antimicrobial peptides from other sources.  22 
Edman degradation sequencing 23 
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Cruzioseptins 10–15 were found first by antimicrobial activity screening of reverse phase 1 
HPLC fractions of C. calcarifer skin secretions from the Costa Rican population. Peptides 2 
were re-chromatographed for purification and sequenced by Edman degradation. The 3 
sequences are shown in Table 2. Later, two of them were cloned from the same population, 4 
but none were cloned from the Ecuadorian population to date. The peptide sequences were 5 
submitted to the UniProt Knowledgebase under accession numbers: C0HK07- C0HK012. 6 
Isolation and structural analysis of cruzioseptin 7 
During functional screening of HPLC fractions of the skin secretion of C. calcarifer, 8 
antimicrobial activity against S. aureus and C. albicans was identified in fractions 162, 163, 9 
171 and 172 (Figure 2). Cruzioseptin-1 was identified in HPLC fractions 171 and 172 based 10 
on its monoisotopic molecular mass [M+H]1+ m/z of 2117.54 as determined by MALDI-TOF 11 
mass spectrometric analysis and confirmed by LCQ ESI MS full scan that revealed ions 2+ = 12 
m/z 1059.75 and 3+ m/z = 706.67 (Figure 3).  In addition, cruzioseptin-2 was identified in 13 
HPLC fractions 162 and163 due to its monoisotopic molecular mass [M+H]+1 m/z of 14 
2427.42, as found by MALDI-TOF and confirmed by a LCQ ESI MS full scan, where ions 15 
2+ m/z = 1215.08, 3+ m/z = 810.50, and 4+ m/z = 316.25, were identified (Figure 4). 16 
It is remarkable that all cruzioseptins 1 to 15 were 100% identified by LCQ MS/MS 17 
fragmentation sequencing employing the whole skin secretion of C. calcarifer (Table 2). 18 
Antimicrobial and haemolytic assays of cruzioseptins 19 
Once sequences were confirmed, cruzioseptins 1-3 were selected for further analysis. CZS 1 20 
and 2 were chosen because these peptides were identified in HPLC fractions as detailed 21 
above, but in order to determine their potency and specificity more pure peptides were 22 
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required. CZS-3 was included later due to the sequence similarity with CZS-2, aiming to 1 
determine the effect of the 3 amino acid differences in its antimicrobial activity.  2 
Cruzioseptins 1, 2 and 3 were synthesized by solid phase Fmoc chemistry, purified by HPLC, 3 
and the sequences were confirmed by LCQ MS/MS sequencing (Figure 5 and 6). Physico-4 
chemical properties of CZS1–3 are summarized in Table 3. Synthetic pure peptides were 5 
employed in antimicrobial and haemolytic assays. Cruzioseptin-1 displayed potent broad-6 
spectrum antimicrobial activity against all three microorganisms tested with MICs of 15.11 7 
µM against E. coli and 3.77 µM against S. aureus and C. albicans. In addition, the MBC was 8 
below 15.11 µM for the three microorganisms. At the antimicrobial concentration of 3.77 9 
µM, this peptide showed only 1% haemolytic activity while reaching 20% haemolysis at 10 
15.11 µM. CZS-1 reached 100% haemolysis at 120.87 µM. In addition, cruzioseptin-2 11 
showed moderate broad-spectrum antimicrobial activity against E. coli (MIC of 26.35 µM), 12 
S. aureus (6.59 µM), and C. albicans (13.18 µM). The MBC concentrations were below 13 
52.69 µM. for the three microorganism.  Nevertheless, haemolytic activity at 13.18 µM was 14 
only 26% reaching 100% haemolysis at 210.96 µM. In contrast, synthetic cruzioseptin-3 was 15 
less potent that CZS-1 and CZS-2 showing MICs of 13.32 µM against the three 16 
microorganisms tested. Moreover, the MBC was similar to CZS-2 (53.31 µM). However, 17 
haemolysis at this concentration was only 6%. CZS-3 produced 100% haemolysis at 213.33 18 
µM. Results of these tests are summarized in Table 4 and Figure 8. 19 
DISCUSSION 20 
Antimicrobial peptides secreted by phyllomedusine frog skins are extremely diverse. At least 21 
eight families of antimicrobial peptides have been reported so far. These peptides have been 22 
classified based on similarities of their primary structures and/or structural motifs. The most 23 
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diverse family is the dermaseptins sensu stricto, which contains more than 75 peptides 1 
described from 15 species [8].  2 
Through a combination of molecular cloning, Edman degradation sequencing, and LCQ 3 
tandem MS/MS, a new family named ‘cruzioseptins’ of 15 antimicrobial peptides were found 4 
in the splendid leaf frog, Cruziohyla calcarifer. All these novel peptides share these unique 5 
structural sequences: (1) the N-terminal motif GFLD–; and (2) the motif –GKAAL(N/G/S) 6 
(V/A)V– or –VALGAVSK–. In fact, 13 of the cruzioseptins (CZS-2 to CZS-14) present the 7 
motif –GKAAL(G/N/S)(V/A)V– and 2 cruzioseptins (CZS-1 and 15) present the motif –8 
VALGAVSK– (Table 2). Their precursor sequences are extremely conserved, sharing high 9 
similarity in the signal and acidic spacer sequences at the N-terminal ends but showing 10 
important variation in the mature sequences at their C-terminal ends. A BLAST/n search in 11 
the NCBI database identified the precursor sequences of these peptides as members of the 12 
dermaseptin superfamily. In addition, the BLAST/p comparisons with the translated mature 13 
sequences of these peptides, showed 45–90% similarity to dermaseptins. However, CZS-1 14 
and CZS-15 did not produce any significant hits when compared with BLAST/p, suggesting 15 
that these were a well differentiated group of peptides that we recognize as a new family 16 
based on having a set of unique shared structural motifs and sequences. With a closer analysis 17 
of CZS-8, 11 and 14 sequences, it was found that the similarities with dermaseptins were 18 
concentrated in the centre of the mature peptides where these cruzioseptins share the 19 
dermaseptin motif –AAGKAALNV–. However, all cruzioseptins lack the characteristic Trp 20 
(W) in position 3 of dermaseptins. For that reason, and for having the motif GFLD– at their 21 
N-terminals, and the motifs –GKAAL(N/G/S) (V/A)V– or –VALGAVSK– at the mid-region, 22 
these novel antimicrobials were not classified as dermaseptins; instead, they were assigned to 23 
a new family of antimicrobial peptides – the cruzioseptins. 24 
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The GFLD– N-terminal motif is also found in other four amphibian skin antimicrobial 1 
peptides, including: ranatuerin-3 from Rana catesbeiana (accession number P82780.1), 2 
brevinins 2PTd and 2Pte from Pulchrana picturata (accession numbers POC8T6.1 and 3 
POC8T7.1, respectively), and frenatin-4 from Litoria infrafrenata (accession number 4 
P82023.1). These species belong to the families Ranidae and Hylidae. However, neither 5 
ranatuerin, brevinin or frenatin families contain GFLD– as a specific motif, so their 6 
appearance in these families is most likely a result of convergent evolution. On the other 7 
hand, the strongly-conserved nucleotide precursor sequences of cruzioseptins at their N-8 
terminals in common with other members of the dermaseptin superfamily, such as litorins 9 
and caerin of the Australian frogs of the Pelodryinae subfamily, supports the view that the 10 
genetic origin of the ancestral gene precursor of cruzioseptins was present in the common 11 
ancestor which originated prior to the fragmentation of Gondwana. In addition, the 12 
extraordinary diversity of cruzioseptins found in a single species provides evidence, once 13 
again, that evolutionary mechanisms such as hypermutability of the C-terminal domain, gene 14 
duplication, and diversifying selection can provide a wide range of antimicrobial protection 15 
[9,31]. 16 
In addition, three cruzioseptins were chemically synthesized and their antimicrobial profiles 17 
were analysed, showing that all three cruzioseptins (CZS1–3) have broad spectra of 18 
antimicrobial activity and relatively low haemolytic activity (Table 4). Firstly, CZS-3 showed 19 
potent activity (MIC) against the Gram negative bacterium E. coli at 13.32 µM, followed by 20 
CZS-1 at 15.11 µM and CZS-2 at 23.35 µM. In addition, at these concentrations, the peptides 21 
presented relatively little haemolysis (6%, 9%, and 26%, respectively) (Table 4 and Figure 22 
8). However, in comparison with other antimicrobial peptides of similar sequences (50–70% 23 
similarity) such as dermaseptin-B4 from P. bicolor (accession number P81486) and 24 
dermadistinctin-L from P. distincta (accession number P83639), cruzioseptins are less potent 25 
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than dermaseptins, whose MICs are 5 and 2.5 µM, respectively (Table 4). Secondly, CZS-1 1 
was the most potent of the three cruzioseptins, being able to inhibit the growth (MIC) of the 2 
Gram positive bacterium S. aureus at 3.77 µM; to achieve the same goal, CZS-2 is 2-fold less 3 
potent and CZS-3 is 3-fold less potent. However, dermaseptin-B4 and dermadistinctin-L are 4 
still more potent (MICs 3.0 µM and 1.3 µM, respectively) [32,33]. Finally, CZS-1 was also 5 
able to inhibit the growth (MIC) of the yeast C. albicans at 3.77 µM while CZS-2 and CZS-3 6 
needed 3-fold this concentration to achieve the same goal (Table 4). Cruzioseptins 1-2 were 7 
bactericidal against E. coli having the same MIC and MBC concentrations. However, 8 
cruzioseptins 1-3 have a bacteriostatic effect against S. aureus and C. albicans, requiring a 9 
two or three folds concentration increase to reach the bactericidal effect (Table 4). This is an 10 
important result because there are relatively few peptides that exhibit antifungal activity and 11 
the need to develop new antifungal agents is always growing. The differences in activity 12 
found between CZS-2 and CZS-3 are very interesting because these peptides are very similar 13 
in their primary structures (87%) and both have a charge of +2. They differ only in 3 amino 14 
acids: I/V in position 6, V/I in position 9 and V/A in position 16 (Table 3).  15 
The predicted secondary structures and physico-chemical properties of the three cruzioseptins 16 
(CZS-1, CZS-2, and CZS-3) are shown in Table 3. All three cruzioseptins have a similar 17 
hydrophobicity (H value range 0.523–0.581) and hydrophobic moment (0.441–0.472 µH), 18 
although the primary structure of CZS-1 compared to CZS-2 and CZS-3 is different sharing 19 
only 12 conserved amino acids (57%). In addition, CZS-1 has a predicted helical domain 20 
containing 19.05 % of the peptide that increases to 30.43% for CZS-3 and decreases to 0% 21 
for CZS-2. Moreover, CZS-1 possesses a higher net positive charge than CZS-2 and CZS-3 22 
(+3 versus +2). Helical wheel plots showed that all three cruzioseptins are amphipathic 23 
having 11–13 amino acids placed in the hydrophobic face (V/ I/ A/ F/ L/ G) and 8–12 amino 24 
acids hydrophilic residues placed at the opposite side (Table 3 and Figure 7).  25 
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These 3 variations in sequence change the potency of CZS-2 making it weaker that CZS-3 1 
against E. coli (13.33 vs 26.35 µM) but more potent against C. albicans (13.33 vs 6.59 µM).  2 
In summary, the antimicrobial potency observed for CZS-1 could be due to its +3 charge, in 3 
contrast to the+2 of CZS-2 and CZS-3. However, in comparison with other antimicrobial 4 
peptides such as dermaseptin-B4 and dermadistinctin-L, CZS-2 is weaker against E. coli, but 5 
potent against S. aureus. Moreover, CZS showed potency against S. aureus and C. albicans 6 
with only 1% haemolysis at those concentrations, which makes CZS-1 an interesting peptide 7 
and warrants further study into its potential antibiotic and antifungal functions.  8 
In conclusion, cruzioseptins, a novel antimicrobial peptide family, is reported in Cruziohyla 9 
calcarifer. Three synthetic cruzioseptins displayed broad-spectrum antimicrobial activity 10 
against S. aureus, C. albicans and less potently against E. coli with minor haemolytic 11 
activity. These data show once again, the phenomenal peptide diversity produced in the skin 12 
of phyllomedusine frogs such as the previously unstudied C. calcarifer. Interplay between 13 
molecular cloning and tandem mass spectrometry sequencing, together with functional 14 
studies of natural and synthetic peptides have proven to be a robust, cost-effective strategy 15 
for peptidomic analysis in species where databases are not available. In addition, these 16 
techniques are sensitive enough to generate data with only a few milligrams of material, and 17 
this is especially beneficial in the analysis of endangered species where samples are limited. 18 
Finally, the discovery of novel natural antimicrobial peptides such as cruzioseptins is a key 19 
element in the development of new therapeutic drugs based on the structures of natural 20 
compounds. 21 
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Table 1. Antimicrobial peptides of Cruziohyla calcarifer identified by molecular cloning. 1 
 2 
Table 2. Amino acid sequences of cruzioseptins confirmed by tandem mass spectrometry 3 
sequencing. Characteristic motifs of cruzioseptins are highlighted. Amidation was predicted 4 
according to the precursor sequence. 5 
 6 
 7 
 8 
 9 
 10 
 11 
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Table 3.  Physico-chemical properties of cruzioseptins 1, 2, 3 from Cruziohyla calcarifer. 1 
 2 
Table 4. Minimal inhibitory concentrations (MICs) and haemolytic activity of synthetic 3 
cruzioseptins from Cruziohyla calcarifer. 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
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Figure 1. Nucleotide and translated open-reading frame amino acid sequences of the sense 1 
strand of cloned cDNAs encoding cruzioseptins 1 to 9, 11 and 12 from Cruziohyla calcarifer. 2 
The putative signal peptides are double-underlined, acidic spacers are in italics, the mature 3 
peptides are single-underlined and the stop codons are indicated by asterisks. Accession 4 
numbers KX065078 and KX065088, respectively. 5 
A) Cruzioseptin-1 (CZS-1). B) Cruzioseptin-2 (CZS-2).C) Cruzioseptin-3 (CZS-3). D) 6 
Cruzioseptin-4 (CZS-4). E) Cruzioseptin-5 (CZS-5). F) Cruzioseptin-6 (CZS-6). G) 7 
Cruzioseptin-7 (CZS-7). H) Cruzioseptin-8 (CZS-8). I) Cruzioseptin-9 (CZS-9). J) 8 
Cruzioseptin-11 (CZS-11). K) Cruzioseptin-12 (CZS-12) L) Domain structure of the 9 
antimicrobial peptide precursors: 1. putative signal peptide. 2–5 acidic spacer peptides. 3, 5. 10 
propeptide convertase processing sites. 6. mature antimicrobial peptide. 7. C-terminal 11 
processing site with glycyl G residue amide donor indicated with an asterisk. 12 
Figure 2. Reverse phase HPLC chromatogram of Cruziohyla calcarifer skin secretion 13 
fractionated over 240 min with dual UV detection at 214 nm (red line) and 280 nm (green 14 
line).  Arrows denote retention times of fractions with antimicrobial activity. Cruzioseptin-1 15 
was identified in fraction 171 and Cruzioseptin-2 in fraction 162.  16 
Figure 3. Mass analysis of antimicrobial HPLC fraction with retention time 171 min 17 
containing Cruzioseptin 1. A) The arrow denotes a singly-charged ion of m/z 2117.54 18 
obtained by MALDI-TOF MS analysis. B) LCQ MS ESI denotes precursor ions of m/z 2+ 19 
1059.75 and 3+ 706.67 corresponding to CZS-1. 20 
Figure 4. Mass analysis of antimicrobial HPLC fraction with retention time 162 min 21 
containing Cruzioseptin 2. A) Arrow denotes a singly charged ion of m/z 2427.42 obtained 22 
by MALDI-TOF MS analysis B) LCQ MS ESI denotes precursor ions of m/z 2+ 1215.08, 3+ 23 
810.50, and 4+ 316.25 corresponding to CZS-2. 24 
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Figure 5. Synthetic cruzioseptins 1, 2, and 3 produced by SPPS and purified by RP-HPLC. 1 
A) Cruzioseptin-1 single charge ion of m/z 2117.63. B) Cruzioseptin-2 single charged ion of 2 
m/z 2427.38. C) Cruzioseptin-3 single charged ion of m/z 2400.61. 3 
Figure 6. LCQ MS/MS Sequencing of Cruzioseptin-1 (A), Cruzioseptin-2 (B), and 4 
Cruzioseptin-3 (C). Each table contains the predicted b and y ions from each sequence. 5 
Observed ions are underlined in blue and red typefaces. 6 
Figure 7. Predicted alpha helical wheel plots of cruzioseptins 1, 2, and 3. Basic residues are 7 
in blue and acid residues are in red. The basic amino acid histidine is in light blue as its 8 
charge depends on pH. Non polar residues are in yellow and polar residues are in purple. 9 
Uncharged residues of glycine and alanine are in grey and asparagine and glutamine are in 10 
pink. The arrow points to the hydrophobic face. 11 
Figure 8. Haemolytic activity of Cruzioseptins 1, 2 and 3. 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
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Figure 1 1 
A) Cruzioseptin-1 2 
               M  A  F   L  K  K   S  L  F  L   V  L  F  3 
       1 TTTAGACCAA ACATGGCTTT CCTGAAGAAA TCTCTTTTCC TTGTATTATT 4 
   L  G  L   V  S  L  S   I  C  E   E  E  K   R  E  E  N  5 
      51 CCTTGGATTG GTCTCTCTTT CGATCTGTGA AGAAGAGAAA AGAGAAGAGA 6 
    E  E  E   Q  D  D   D  E  Q  S   E  E  K   R  G  F 7 
     101 ATGAAGAGGA ACAAGACGAT GATGAGCAAA GTGAAGAGAA GAGAGGCTTC 8 
   L  D  I  V   K  G  V   G  K  V   A  L  G  A   V  S  K  9 
     151 CTGGATATAG TAAAAGGTGT AGGAAAAGTG GCTTTAGGTG CAGTTAGTAA 10 
   L  F  G   Q  E  E  R   * 11 
     201 ACTTTTCGGT CAAGAAGAAC GATAAAGTTA AGAAAATGTG ATATGTCATT 12 
     251 ACTCTAAGGA GTACAATTAT GAATAATTGT TCCAAACCTA TATAAAAAAA 13 
     301 AAAAAAAAAA AAAAA 14 
 15 
B) Cruzioseptin-2 16 
                  M  A  F   L  K  K   S  L  F  L   V  L  F  17 
       1 TTTAGACCAA ACATGGCATT CCTGAAGAAA TCCCTTTTCC TTGTACTATT 18 
   L  G  L   V  S  L  S   I  C  E   E  E  K   R  E  E  E  19 
      51 CCTTGGATTG GTCTCTCTTT CTATCTGTGA AGAAGAGAAA AGAGAAGAGG 20 
    N  E  E   V  Q  E   D  D  D  Q   S  E  E   K  R  G 21 
     101 AGAATGAGGA GGTACAAGAA GATGATGATC AAAGTGAAGA GAAGAGAGGC 22 
   F  L  D  V   I  K  H   V  G  K   A  A  L  G   V  V  T  23 
     151 TTCCTGGATG TAATAAAACA TGTAGGAAAA GCGGCTTTAG GTGTAGTTAC 24 
   H  L  I   N  Q  G  E   Q  * 25 
     201 TCACCTGATA AATCAAGGAG AACAATAAAG TCATGAAAAT GTGAAATGTC 26 
     251 ATTACTCTAA GGAGTACAAT TATCAATAAT TGTGCCAAAC CTATATTAAA 27 
     301 GCATATTGAA CTGACAAAAA AAAAAAAAAA AAAAAAAAAA 28 
 29 
C) Cruzioseptin-3 30 
   K  R  G   F  L  D  V   V  K  H   I  G  K   A  A  L  G  31 
       1 AAGAGAGGCT TCCTGGACGT AGTAAAACAT ATAGGAAAAG CGGCTTTAGG 32 
  · A  V  T   H  L  I   N  Q  G  E   Q  *  33 
      51 TGCAGTTACT CACCTGATAA ATCAAGGAGA ACAATAAAGT CATGAAAAAG 34 
     101 TGAAATTTCA TTACTCTGAG TACAATTATC AAAAAATGTG CCAAATCTAT 35 
     151 ATTAAAAGAT ATTGAACAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA 36 
 37 
D) Cruzioseptin-4 38 
   K  R  G   F  L  D  V   I  K  H   V  G  K   A  A  L  S· 39 
       1 AAGAGAGGCT TCCTGGATGT AATAAAACAT GTAGGAAAAG CTGCTTTAAG 40 
    V  V  S   H  L  I   N  E  G  E   H  *  41 
      51 TGTAGTTTCT CATCTGATTA ATGAAGGGGA ACATTAAGGT CATGAATATG 42 
     101 TGAAATGTCA TTACTCTAAG GAGTACTCTT ATGAGTAATT GTGCCAAACC 43 
     151 TATATTAAAG CCTATTGTAC AGCATATTGA AAAAAAAAAA AAAAAAAAA 44 
 45 
E) Cruioseptin-5 46 
   K  R  G   F  L  D  V   I  K  H   V  G  K   A  V  G  K· 47 
       1 AAGAGAGGCT TCCTGGATGT AATAAAACAT GTAGGAAAAG CTGTAGGAAA 48 
  · A  A  L   N  A  V   N  D  M  V  N  K  P   E  Q  Q  S· 49 
      51 AGCGGCTTTA AATGCAGTTA ATGATATGGT AAATAAACCA GAGCAACAAA 50 
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  · *  1 
     101 GTTGAGAAAA TGTAAAACAG AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2 
     151 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3 
 4 
F) Cruzioseptin-6 5 
   M  A  Y   L  K  K  S   L  F  L   V  L  F   L  G  L  V· 6 
       1 ATGGCTTACC TGAAGAAATC TCTTTTCCTT GTACTATTCC TTGGATTGGT 7 
  · S  L  S   I  C  E   E  E  K  R   E  E  E   N  E  E   8 
      51 CTCTCTTTCG ATCTGTGAAG AAGAGAAAAG AGAAGAGGAG AATGAGGAGG 9 
  E· Q  E  D   D  D  Q   S  E  E   K  R  G  F   L  D  V. 10 
     101 AACAAGAAGA TGATGATCAA AGTGAAGAGA AGAGAGGCTT CCTGGATGTA 11 
   I  T  H   V  G  K  A   V  G  K   A  A  L   N  A  V  T · 12 
     151 ATAACACATG TAGGAAAAGC TGTAGGAAAA GCGGCTTTAA ATGCAGTTAC 13 
    E  M  V   N  Q  A   E  Q  *. 14 
     201 TGAAATGGTA AATCAAGCAG AGCAATAA                         15 
 16 
G) Cruzioseptin-7 17 
   M  A  K   L  K  K  S   L  F  L   V  L  F   L  G  L  V· 18 
       1 ATGGCTAAAT TGAAGAAATC TCTTTTCCTT GTGCTATTCC TTGGATTGGT 19 
  · S  L  S   I  C  E   E  E  K  R   E  E  E   N  E  E  · 20 
      51 CTCTCTTTCG ATCTGTGAAG AAGAGAAAAG AGAAGAGGAG AATGAGGAGG 21 
  V  Q  E  D   D  D  Q   S  E  E   K  R  G  F   L  D  V  22 
     101 TACAAGAAGA TGATGATCAA AGTGAAGAGA AGAGAGGCTT CCTGGATGTA 23 
   V  K  H   V  G  K  A   V  G  K   A  A  L   N  A  V  T · 24 
     151 GTAAAACATG TAGGAAAAGC TGTAGGAAAA GCGGCTTTAA ATGCAGTTAC 25 
  · E  M  V   N  Q  A   E  Q  *  26 
     201 TGAAATGGTA AATCAAGCAG AGCAATAAAG TTGAGAAAAT GTAAAATCGA 27 
     251 CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA A 28 
 29 
H) Cruzioseptin-8 30 
   M  A  F   L  K  K  C   L  F  L   V  L  F   L  G  L  V· 31 
       1 ATGGCTTTCC TGAAGAAATG TCTTTTCCTT GTACTATTCC TTGGATTGGT 32 
  · S  L  S   I  C  E   E  E  K  R   E  E  E   N  E  E   33 
      51 CTCTCTTTCG ATCTGTGAAG AAGAGAAAAG AGAAGAGGAG AATGAGGAGG 34 
  V· Q  E  D   D  D  Q   S  E  E   K  R  G  F   L  D  V 35 
     101 TACAAGAAGA TGATGATCAA AGTGAAGAGA AGAGAGGCTT CCTGGATGTA 36 
   I  K  H   V  G  K  A   A  G  K   A  A  L   N  A  V  T· 37 
     151 ATAAAACATG TAGGAAAAGC TGCAGGAAAA GCGGCTTTAA ATGCAGTTAC 38 
    E  M  V   N  Q  G   E  Q  *  39 
     201 TGAAATGGTA AATCAAGGAG AGCAATAACG TTAAGAAAAT GTAAAATCTA 40 
     251 ATTACTCTAA GGAGTACAAT TATCAATAAT TGTGCCAAAC CTATATTAAA 41 
301 GCATATTGAA CTGATAAAAA AAAAAAAAAA AAAAAAAAAA AAAA 42 
 43 
I) Cruzioseptin-9 44 
   K  R  G   F  L  D  V   I  T  H   V  G  K   A  V  G  K· 45 
       1 AAGAGAGGCT TCCTGGATGT AATAACACAT GTAGGAAAAG CTGTAGGAAA 46 
  · A  A  L   N  A  V   N  E  M  V   N  Q  G   E  Q  *  47 
      51 AGCGGCTTTA AATGCAGTTA ATGAAATGGT AAATCAAGGA GAGCAATAAC 48 
     101 GTTGAGAAAA TGTAAAATCG AATTGCGCTA AGAAGTAAAA TTATTATTAA 49 
     151 ACTGAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA 50 
 51 
J) Cruzioseptin-11 52 
   M  V  K   L  K  K  S   L  F  L   V  L  F   L  G  L  V · 53 
       1 ATGGTTAAAC TGAAGAAATC TCTTTTCCTT GTATTATTCC TTGGATTGGT 54 
  · S  L  S   I  C  E   E  E  K  R   E  E  E   N  E  E  V · 55 
      51 CTCTCTTTCT ATCTGTGAAG AAGAGAAAAG AGAAGAGGAG AATGAGGAGG 56 
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  ·  Q  E  D   D  D  Q   S  E  E   K  R  G  F   L  D  I 1 
     101 TACAAGAAGA TGATGATCAA AGTGAAGAGA AGAGAGGCTT CCTGGATATA 2 
   V  K  H   V  G  K  A   A  G  K   A  A  L   N  A  V  T· 3 
     151 GTAAAACATG TAGGAAAAGC TGCAGGAAAA GCAGCTTTAA ATGCAGTTAC 4 
  · E  M  V   N  Q  G   E  Q  *  5 
     201 TGAAATGGTA AATCAAGGAG AGCAATAAAG TTAAGAAAAT GTAAAATCTA 6 
     251 ATTACTCTAA GGAGTACAAT TATCAATAAT TGTGCCAAAC CTATATTAAA 7 
     301 GCATTTTGAA CAAAAAAAAA AAAAAAAAAA AAAAAAA 8 
 9 
K) Cruzioseptin-12 10 
   M  A  F   L  K  K  S   L  F  L   V  L  F   L  G  L  V· 11 
       1 ATGGCTTTCC TGAAGAAATC TCTTTTCCTT GTACTATTCC TTGGATTGGT 12 
  · S  L  S   I  C  E   E  E  K  R   E  E  E   N  E  E   13 
      51 CTCTCTTTCG ATCTGTGAAG AAGAGAAAAG AGAAGAGGAG AATGAGGAGG 14 
  V· Q  E  D   D  D  Q   S  E  E   K  R  G  F   L  D  V 15 
     101 TACAAGAAGA TGATGATCAA AGTGAAGAGA AGAGAGGCTT CCTGGATGTA 16 
   V  K  H   V  G  K  A   V  G  K   A  A  L   N  A  V  N· 17 
     151 GTAAAACATG TAGGAAAAGC TGTAGGAAAA GCGGCTTTAA ATGCAGTTAA 18 
  · D  L  V   N  Q  G   E  Q  * 19 
     201 TGATTTGGTA AATCAAGGAG AGCAATAAAG TTAAGAAGAT GTAAAATCGA 20 
     251 ATTGCGCTAA GAAGTAAAAT TATTATTAAA CTGAGAAAAA AAAAAAAAAA 21 
     301 AAAAAAAAAA A 22 
 23 
L) 24 
      --------1-------  2  3 -----4-----  5 ----------6-----------  7 25 
CZS-1  MAFLKKSLFLVLFLGLVSLSIC EEE KR EENEEEQDDDEQSEE  KR GFLDIVKGVGKVALGAVSKLF         G* QEER 26 
CZS-2  MAFLKKSLFLVLFLGLVSLSIC EEE KR EEENEEVQEDDDQSEE KR GFLDVIKHVGKAALGVVTHLINQ       G* EQ 27 
CZS-3                                                 KR GFLDVVKHIGKAALGAVTHLINQ       G* EQ 28 
CZS-4                                                 KR GFLDVIKHVGKAALSVVSHLINE       G* EH 29 
CZS-5                                                 KR GFLDVIKHVGKAVGKAALNAVNDMVNKPEQQS 30 
CZS-6  MAYLKKSLFLVLFLGLVSLSIC EEE KR EEENEEEQEDDDQSEE KR GFLDVITHVGKAVGKAALNAVTEMVNQAEQ 31 
CZS-7  MAKLKKSLFLVLFLGLVSLSIC EEE KR EEENEEVQEDDDQSEE KR GFLDVVKHVGKAVGKAALNAVTEMVNQAEQ 32 
CZS-8  MAFLKKCLFLVLFLGLVSLSIC EEE KR EEENEEVQEDDDQSEE KR GFLDVIKHVGKAAGKAALNAVTEMVNQ   G* EQ 33 
CZS-9                                                 KR GFLDVITHVGKAVGKAALNAVNEMVNQ   G* EQ 34 
CZS-11 MVKLKKSLFLVLFLGLVSLSIC EEE KR EEENEEVQEDDDQSEE KR GFLDIVKHVGKAAGKAALNAVTEMVNQ   G* EQ 35 
CZS-12 MAFLKKSLFLVLFLGLVSLSIC EEE KR EEENEEVQEDDDQSEE KR GFLDVVKHVGKAVGKAALNAVNDLVNQ   G* EQ 36 
 37 
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Figure 3 1 
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171 #3-7 RT: 0.02-0.05 AV: 5 NL: 6.50E2
T: ITMS + p ESI Full ms [150.00-2000.00]
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Figure 4 1 
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162 #4-9 RT: 0.03-0.07 AV: 6 NL: 6.90E2
T: ITMS + p ESI Full ms [150.00-2000.00]
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Figure 6 1 
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Figure 8 1 
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